WO2011144791A1 - Méthode pour le pronostic et le diagnostic de la sténose aortique dans laquelle l'alpha-1-antichimotrypsine est utilisée en tant que marqueur - Google Patents

Méthode pour le pronostic et le diagnostic de la sténose aortique dans laquelle l'alpha-1-antichimotrypsine est utilisée en tant que marqueur Download PDF

Info

Publication number
WO2011144791A1
WO2011144791A1 PCT/ES2011/070365 ES2011070365W WO2011144791A1 WO 2011144791 A1 WO2011144791 A1 WO 2011144791A1 ES 2011070365 W ES2011070365 W ES 2011070365W WO 2011144791 A1 WO2011144791 A1 WO 2011144791A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
fragment
expression product
Prior art date
Application number
PCT/ES2011/070365
Other languages
English (en)
Spanish (es)
Inventor
Tatiana MARTÍN-ROJAS
Félix GIL-DONES
Verónica MORAL DARDÉ
Luís RODRÍGUEZ PADIAL
Fernando De La Cuesta Marina
Gloria Alvarez-Llamas
Fernando VIVANCO MARTÍNEZ
Mª Eugenia GONZÁLEZ BARDERAS
Original Assignee
Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin) filed Critical Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin)
Publication of WO2011144791A1 publication Critical patent/WO2011144791A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Definitions

  • the present invention relates to a method of obtaining useful data for the determination of the risk of suffering aortic stenosis (AD), the presence of AD and / or the prognosis of the development of an AD, by detecting and / or quantifying the ⁇ -1-antichymotrypsin protein.
  • the present invention relates to a diagnosis and prognosis kit for AD.
  • AD Alzheimer's disease
  • AD degenerative AD has been considered an inevitable consequence of aging and was thought of as a passive process secondary to calcium deposition in the aortic valve.
  • etiology is not known with certainty, several authors have indicated that it shares the same risk factors as atherosclerosis, since AD is more frequent in patients with hypercholesterolemia, arterial hypertension, smoking and diabetes (Nalini et al Circulation 2003; 107: 2181-84).
  • ⁇ -1-anti-chymotrypsin is an alpha globulin glycoprotein that is a member of the serpine family.
  • the ⁇ -1-antichymotrypsin inhibits some proteases such as cathepsin and is protective of the damage caused by proteolytic enzymes.
  • proteases such as cathepsin
  • the present invention provides a method of obtaining useful data for the determination of aortic stenosis (AD) or of the risk of suffering from AD or of the evolution of an AD quickly, easily and efficiently. Also, the present The invention relates to the use of a kit to determine the risk of suffering from AD or to determine the presence of an AD or to predict the progression of an AD, in an isolated biological sample.
  • the present invention therefore provides a response to the need for biomarkers that allow diagnosis and prognosis of AD.
  • the present invention solves the technical problem of finding a good biomarker for AD, if possible that it can be monitored in plasma or blood serum, that is, it does not imply obtaining a more invasive biological sample.
  • a-1 - antichymotrypsin has high levels in the stenotic aortic valve tissue, in its secrecy as well as in the blood plasma of patients with AD, in relation to the levels of individuals control.
  • a first aspect of the invention relates to a method of obtaining useful data (hereinafter method of the invention) for the determination of AD or the risk of suffering from AD or the evolution of an AD comprising:
  • SEQ ID NO: 1 or a fragment of said expression product, in the sample obtained in step (a).
  • aortic stenosis refers to aortic valve stenosis, which is a valvulopathy (valvular heart disease) characterized by abnormal narrowing of the aortic valve orifice of the heart . This reduction of the valvular orifice can be congenital or acquired.
  • AD determination of AD
  • determination of AD refers to, but is not limited to, the finding of the presence of AD in a subject.
  • risk of suffering from AD refers to, but is not limited to, the predisposition of a subject to suffer or Develop an EA. Therefore, the method refers to obtaining useful data to determine if a subject is developing or can develop an EA.
  • AD evolution of AD
  • % identity refers to the% identity between two amino acid sequences.
  • The% identity is the result of counting the number of positions along the alignment of two sequences where all amino acids in the same position are identical.
  • the expression product or fragment thereof, detected and / or quantified in step (b) may encode for an amino acid sequence at least 55, 60, 65, 70, 75, 80, 85, 90 or 95% identical to SEQ ID NO: 1.
  • expression product refers to the product resulting from the transcription (RNA) or translation (protein) of a gene or a nucleotide sequence of DNA, or any resulting form of the processing of the product resulting from the transcription or expression of a gene or a nucleotide sequence of DNA.
  • ⁇ -1-antichymotrypsin gene refers to the DNA sequence encoding the ⁇ -1-antichymotrypsin protein, a variant of the ⁇ -1-antichymotrypsin protein or a fragment thereof, as long as said variant or said fragment is functionally equivalent.
  • the amino acid sequence SEQ ID NO: 1 is the amino acid sequence of the Homo sapiens (human) ⁇ -1-antichymotrypsin protein with accession number NP_001076.2 from the NCBI database.
  • the expression product or fragment thereof, detected and / or quantified in step (b) encodes an amino acid sequence having at least 70% identity with SEQ ID NO: 1.
  • said expression product encodes for the amino acid sequence SEQ ID NO: 1 or for a fragment thereof.
  • the method of the invention further comprises comparing the data obtained in step (b) with standard values to find a significant deviation.
  • the method of the invention further comprises attributing the significant deviation to the presence of AD or the risk of suffering from AD in the subject of (a).
  • the biological sample from step (a) is a biological fluid. More preferably, the biological fluid is blood or serum or blood plasma.
  • the biological sample from step (a) comprises cells.
  • it comprises a fabric.
  • the biological sample from step (a) is an isolated sample of an organism such as the human or animal body and may come from a physiological fluid and / or any cell or tissue of an organism.
  • the biological sample isolated in step (a) of the method of the invention comprises cells. More preferably, these cells are aortic valve.
  • the biological sample may be a tissue, for example, but not limited to, a biopsy or a fine needle aspirate. Even more preferably, the biological sample isolated in step (a) may be an aortic valve tissue.
  • the biological sample isolated in step (a) of the method of the invention is a biological fluid.
  • the biological fluid may include excreted or secreted fluids from the body, as well as fluids that are not normally.
  • Biological fluid may include, but is not limited to, amniotic fluid surrounding the fetus, aqueous humor, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), saliva, sebum (skin fat), serum , sweat, tears, urine, pericardial fluid, blood and blood plasma.
  • the biological fluid is blood, blood plasma or blood serum.
  • the biological sample isolated in step (a) of the method of the invention can be, for example, but not limited to, fresh, frozen, fixed or embedded in paraffin.
  • Said signal can be obtained, for example, by measuring an intensity value of a chemical or physical property of the ⁇ -1-anti-chymotrypsin gene expression product.
  • the indirect measure includes the measure obtained from a secondary component (for example, a component other than expression products) or a biological measurement system (for example the measurement of cellular responses, ligands, "tags" or enzymatic reaction products) .
  • the term "compare,” as used in the description of the first method of the invention, refers to, but is not limited to, the comparison of the amount of expression product of the ⁇ -1-antichymotrypsin gene of the biological sample. to be analyzed, also called a biological problem sample, with an amount of expression product of the ⁇ -1-antichymotrypsin gene of a desirable reference sample, described elsewhere in the present description.
  • the reference sample can be analyzed, for example, simultaneously or consecutively together with the problem biological sample.
  • the comparison of step (c) of the method of the invention can be performed manually or assisted by a computer.
  • standard values refers to the absolute or relative amount of expression product of the ⁇ -1-antichymotrypsin gene that allows discriminating the presence of AD.
  • Suitable standard values can be determined by the method of the present invention from a reference sample that can be analyzed, for example, simultaneously or consecutively, together with the problem biological sample. More preferably, the standard values may be derived from the normal distribution limits of a physiological amount found in a population of control subjects. Said physiological amount can be determined by several well-known techniques, such as, for example, the calculation of the average amount of expression product of the ⁇ -1-antichymotrypsin gene in a population of control subjects determined by the method of the present invention.
  • the significant deviation can be established by one skilled in the art by using different statistical tools, for example, but not limited, by determining confidence intervals, determining the p-value, Student's test or Fisher's discriminant functions.
  • the confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
  • the value of p is less than 0.1, 0.05, 0.01, 0.005 or 0.0001.
  • the present invention allows the disease to be correctly detected in at least 60%, in at least 70%, in at least 80%, or in at least 90% of the subjects of a certain group or population analyzed.
  • the detection of the amount of expression product of the ⁇ -1-antichymotrypsin gene can be carried out by any method known in the state of the art.
  • the detection of the gene expression product is performed by analyzing the level of messenger RNA (mRNA) derived from its transcription, where the mRNA level analysis can be performed, for example, but not limited, by amplification by polymerase chain reaction (PCR), back transcription in combination with polymerase chain reaction (RT-PCR), back transcription in combination with ligase chain reaction (RT-LCR) , or any other method of nucleic acid amplification; DNA microarrays made with oligonucleotides deposited by any mechanism; DNA microarrays made with oligonucleotides synthesized in situ by photolithography or by any other mechanism; in situ hybridization using specific probes labeled with any method of marking; by electrophoresis gels; by membrane transfer and hybridization with a specific probe; by nuclear magnetic resonance or any other imaging technique using paramagnetic nanoparticles or any other type of detectable nanoparticles functionalized with antibodies or by any other means.
  • PCR polymerase chain reaction
  • RT-PCR polymerase chain reaction
  • the expression product of the nucleotide sequence of the ⁇ -1-antichymotrypsin gene or the fragment of said expression product, which is detected and / or quantified in step (b) of the method of the invention is a amino acid sequence having at least 50% identity with SEQ ID NO: 1, or a fragment thereof. More preferably, it is an amino acid sequence that has at least 70% identity with SEQ ID NO: 1, or a fragment thereof. Even more preferably, it is SEQ ID NO: 1, or a fragment thereof.
  • step (b) of the method of the invention is performed by electrophoresis, immunoassay, chromatography, microarray technology and / or mass spectrometry.
  • step (b) of the method of the invention can be carried out by any combination of any of the mentioned techniques. Detection can be performed by evaluating the presence or absence of the expression product or fragment thereof.
  • Electrophoresis is an analytical separation technique based on the movement or migration of macromolecules dissolved in a medium (the electrophoresis buffer), through a matrix or a solid support, as a result of the action of an electric field.
  • the behavior of the molecule depends on its electrophoretic mobility, which in turn depends on the charge, size and shape of the molecule.
  • the electrophoresis can be chosen from the list comprising: capillary electrophoresis, paper electrophoresis, agarose gel electrophoresis, polyacrylamide gel electrophoresis, isoelectric or electro-focused focusing or two-dimensional electrophoresis.
  • An immunoassay is a biochemical assay that measures the concentration of a substance in a biological sample using a reaction of an antibody or antibodies against its antigen.
  • the assay is based on the specific binding of an antibody with its antigen.
  • the detection and / or quantification of the antibody and / or the antigen can be carried out with various methods.
  • One of the most common is the antigen or antibody mapping.
  • This tide may consist, although without be limited, in an enzyme, a radioisotope (radioimmunoassay), a magnetic marker (magnetic immunoassay) or a fluorophore.
  • radioisotope radioisotope
  • magnetic marker magnetic immunoassay
  • fluorophore fluorophore
  • Heterogeneous immunoassays can be competitive or non-competitive.
  • a competitive immunoassay the response is inversely proportional to the antigen concentration of the sample.
  • a non-competitive assay also called a sandwich assay, the results are directly proportional to the antigen concentration.
  • An immunoassay technique that can be used in the present invention is the enzyme-linked immunoadsorbent assay or ELISA ("Enzyme-Linked ImmunoSorbent Assay").
  • the immunoassay is an immunoblot.
  • a protein extract is obtained from an isolated biological sample of a subject and the proteins are separated by electrophoresis in a support medium capable of retaining them. Once the proteins are separated, they are transferred to a different support or membrane where they can be detected through the use of specific antibodies that recognize the ⁇ -1-antichymotrypsin protein, its variants or fragments thereof.
  • This membrane is hybridized with a first specific antibody (or primary antibody) that recognizes the ⁇ -1-anti-chymotrypsin protein, its variant or a fragment thereof.
  • the membrane is then hybridized with a second antibody (or secondary antibody) capable of specifically recognizing the primary antibody and which is conjugated or bound with a marker compound.
  • a second antibody or secondary antibody
  • it is the primary antibody that recognizes the ⁇ -1-antichymotrypsin protein, its variant or a fragment thereof, that is conjugated or bound to a marker compound, and the use of a secondary antibody is not necessary.
  • Different formats, supports and techniques that can be used for the realization of this preferred aspect of the method of the invention are known in the state of the art.
  • the immunoassay is an immunohistochemistry.
  • Immunohistochemical techniques allow the identification, on tissue or cytological samples of characteristic antigenic determinants. Immunohistochemical analysis is performed on tissue cuts, either frozen or included in paraffin, from an isolated biological sample of a subject. These sections hybridize with a specific antibody or primary antibody that recognizes the ⁇ -1-antichymotrypsin protein, its variants or fragments thereof. The sections are then hybridized with a secondary antibody capable of specifically recognizing the primary antibody and which is conjugated or bound with a marker compound. In an alternative embodiment, it is the primary antibody that recognizes the ⁇ -1-antichymotrypsin protein, its variant or a fragment thereof, that is conjugated or bound to a marker compound, and the use of a secondary antibody is not necessary.
  • the molecules can be separated according to their load, their size or their molecular weight, their polarity or their redox potential, among others.
  • the chromatographic technique can be, but not limited to, liquid chromatography (partition, absorption, exclusion, ion exchange), gas chromatography or supercritical fluid chromatography.
  • the microarray technology of the present invention is based, for example, but not limited to the fixation on a solid support of a molecule that recognizes the expression product of the present invention.
  • the antibody microarray is one of the most common protein microarrays. In this case the antibodies are placed in small points, fixed on the solid support (called a protein chip) and used to capture molecules and thus detect the proteins in a biological sample, such as a cell lysate, a conditioned medium, serum or urine
  • solid support refers to a wide variety of materials, for example, but not limited to, ion exchange resin or adsorption, glass, plastic, latex, nylon, gel, esters or Cellulose, paramagnetic spheres or a combination of some of them.
  • step (b) of the method of the invention is performed by liquid chromatography coupled to tandem mass spectrometer (LC-MS / MS).
  • Another aspect of the invention relates to the use of the expression product of the ⁇ -1-anti-chymotrypsin gene or a fragment thereof, as a marker: a) for the determination of the risk of suffering from AD,
  • the expression product may encode for an amino acid sequence at least 55, 60, 65, 70, 75, 80, 85, 90 or 95% identical to SEQ ID NO: 1 or a fragment thereof.
  • Another aspect of the invention relates to the use of an amino acid sequence having at least 50% identity with SEQ ID NO: 1, or a fragment thereof, as a marker:
  • the amino acid sequence is at least 55, 60, 65, 70, 75, 80, 85, 90 or 95% identical to SEQ ID NO: 1 or a fragment thereof.
  • the amino acid sequence has at least one
  • amino acid sequence is SEQ ID NO: 1 or a fragment of SEQ ID NO: 1.
  • kits comprising primers and / or probes that hybridize with the sequence of an ⁇ -1-antichymotrypsin gene encoding an amino acid sequence having at least 50% or at least 70 % identity with SEQ ID NO: 1, or coding for SEQ ID NO: 1, to determine the risk of suffering from AD or to determine the presence of an EA or to predict the progression of an EA, in an isolated biological sample.
  • primers refers to oligonucleotides with identical or complementary reverse nucleotide sequences that allow amplification of some fragment of the ⁇ -1-antichymotrypsin gene by, for example, polymerase chain reaction (PCR).
  • primer refers to sequences of between 15-30 nucleotides that hybridize with one of the template nucleic acid chains and allow amplification of a DNA sequence by a PCR reaction.
  • probe refers to an identical or complementary reverse RNA or DNA sequence to the a-1 gene sequence - anti-chymotrypsin, capable of hybridizing with said sequence and which may or may not be labeled with any marker compound known in the state of the art,.
  • kits comprising antibodies capable of binding to an amino acid sequence that has at least 50% or at least 70% identity with SEQ ID NO: 1, or that codes for SEQ ID NO: 1, or a fragment thereof, to determine the risk of AD or to determine the presence of an EA or to predict the progression of an EA, in an isolated biological sample.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, that is, molecules that contain a binding site and binding of antigen that specifically binds (immunoreacts ) with a protein.
  • immunoglobulin M immunoglobulin M
  • IgD immunoglobulin D
  • IgG immunoglobulin G
  • IgA immunoglobulin A
  • IgE immunoglobulin E
  • Figure 1 Shows a representative image of a two-dimensional gel of aortic valve tissue made using 2D-DIGE and subsequently stained with silver. Surrounded by a circle, the protein spot is shown whose expression varies when comparing patients with AD with healthy individuals. B) It shows a 3-dimensional scheme of the variation in the expression of the protein highlighted in (A) between individuals with AD and control individuals.
  • FIG. 1 Shows an immunohistochemistry of healthy and stenotic aortic valves against a-1 -antiquimotripsin. 6 ⁇ cryosections of valve tissue with EA and healthy valve tissue were used. The results show increased expression of ⁇ -1-antichymotrypsin in valve sections with AD when compared to healthy valves. As a negative control, an immunohistochemistry was performed without incubation with the antibody against a-1-anti-chymotrypsin.
  • Figure 3 It shows immunoblots where a greater expression of ⁇ -1-antichymotrypsin is confirmed in samples from patients with AD compared to control patients.
  • A) Two-dimensional electrophoresis of aortic valve tissue samples from patients with AD and from control individuals. In the anti-a-1-antichymotrypsin screening, an over-expressed protein spot of 70 kDa was detected in patients with AD versus healthy individuals. Graphical representation of the amount of protein in the control sample (C) and in the sample of patients with AD (AD) in arbitrary units.
  • Figure 4 Shows the MRM chromatograms where the most characteristic transitions are observed for each of the two proteotypic peptides selected from the ⁇ -1-antichymotrypsin.
  • B) Shows the graphical representation of the mean values and standard deviation for each transition corresponding to three independent injections of each sample in the 4000-Qtrap (Applied Biosystems) mass spectrometer.
  • EXAMPLE 01 Detection and quantification of ⁇ -1-antichymotrypsin in samples of patients with AD and control individuals
  • Table 1 Clinical characteristics of the individuals in the control group.
  • valves with EA were processed within a maximum period of 2 hours since the surgery was performed, maintaining the tissue at 4 0 C in RPMI medium. They were washed 3 times with phosphate buffer to reduce blood contaminants. The control valves were processed in a maximum time of 8 hours from the death of the individual.
  • a valve fragment was frozen in liquid nitrogen and homogenized with mortar. Between 0.1-0.3 g of the powder obtained was resuspended in 400 ⁇ of protein extraction buffer (10 mM Tris pH 7.5, 500mm NaCI, 0.1% Triton X-100, 1% ⁇ -mercaptoethanol, 1 mM PMSF). The homogenate was centrifuged at 21,000 g for 15 minutes at 4 0 C.
  • the supernatant (E1) was collected and stored at -20 0 C.
  • the pellet was solubilized in lysis buffer (7 M Urea, 2M Tiourea, 4% CHAPS) and centrifuged again at 21,000 g.
  • This second supernatant (E2) was enriched in hydrophobic proteins, mainly membrane proteins. Cell debris and lipids were eliminated.
  • Both protein extracts E1 and E2 were analyzed together for the analysis of differential two-dimensional electrophoresis (2D-DIGE). The protein concentration was determined by the Bradford-Lowry method.
  • Two-dimensional electrophoresis (2-DE) Protein extracts were resuspended in rehydration buffer (7M urea, 2M thiourea, 4% CHAPS, 1% TBP, 2% ampholytes) and applied to IPG strips of pH 4-7.
  • the isoelectroenfoque (IEF) was developed horizontally and at a constant temperature of 20 ° C. Once the IEF was finished, the strips were balanced to facilitate the passage of the proteins to the second dimension. Protein separation was performed according to the molecular weight in 12% SDS-PAGE gels, using Protean II system (Bio-Rad) at 25mA / gel at 4 0 C. Next, the gels were stained with silver. This protocol is compatible with mass spectrometry. Finally, the gels were scanned with the GS-800 Calibrated Densitometer (Bio-Rad).
  • DIGE Differential two-dimensional electrophoresis
  • the samples were labeled according to the instructions of the commercial house (GE Healthcare, Piscataway, NJ), 50 ⁇ g of protein extract of stenotic aortic valves and 50 ⁇ g of protein extract of aortic control valves were marked with 400 pmol (1 ⁇ ) of fluorochrome corresponding, Cy3 or Cy5, depending on the experimental design.
  • an internal control with all the samples of the experiment was prepared by placing in a single tube 50 ⁇ g of each of the samples and marking the mixture with Cy2. The samples were incubated on ice for 30 minutes in the dark to allow the tidal reaction. This reaction was stopped by adding 1 ⁇ of 10 mM lysine for every 50 ⁇ g of sample and incubating again on ice for 10 minutes and in the dark.
  • the stenotic valve sample, the control valve sample and the pool of all the samples object of the experiment were mixed (150 ⁇ g of total protein), according to experimental design, diluted in rehydration buffer (30 mM TRIS, 7m urea, 2M thiourea, CHAPS 4%) and applied to the 24 cm IPG strips pH 4-7.
  • the first dimension was made in the IPGphor III System (GE Helathcare) following the following IEF program: 500 V for 30 minutes, 1000 V for 1 h, 2000V in 1 h in linear gradient, 5000V in 2 h in linear gradient, 8000V in 1 h in linear gradient, and from 8000V to 88000v / h.
  • the strips were equilibrated with equilibration buffer (TriCI pH 8.8 1, 5 M, 6M urea, 87% glycerol, 2% SDS). Subsequently, the proteins were separated on 12% acrylamide / bisacrylamide 12% SDS-PAGE gels.
  • equilibration buffer TriCI pH 8.8 1, 5 M, 6M urea, 87% glycerol, 2% SDS.
  • the relative protein quantification in the samples of stenotic and healthy valves was carried out through the DeCyder v6.5 program ( Figure 1 B) and with the multivariate statistical module EDA (from English, "Extended data analysis") using the DIA module (from English, "Differential in-gel analysis”), which detects and quantifies the protein spots of the three images corresponding to each gel.
  • the algorithm used by this module for the detection of stains is based on the co-detection of the three fluorescent signals (2 samples and 1 internal control) and makes it possible to differentiate the true protein spots from the gel artifacts.
  • the quantification is based on the calculation of the Cy3 / Cy2 and Cy5 / Cy2 ratios, which allows for a standardized intensity value for each spot.
  • PCA Principal Component Analysis
  • Differentially expressed protein spots were trimmed from the gels manually, automatically digested using the "Ettan Digester” (GE Healthcare) and identified.
  • the gel fragments were reduced using 10 mM dithiothreitol (DTT) in 50 mM ammonium bicarbonate (99% purity) and alkylated with 55 mM iodoacetamide in 50 mM ammonium bicarbonate.
  • the gel fragments were then washed with 50 mM ammonium bicarbonate, 50% methanol (for HPLC) and acetonitrile (for HPLC) after which they were dried in "speedvac” (Thermo Fisher).
  • the spectra were acquired in ion-positive mode with an Nd: YAG laser of 355 nm wavelength, at a frequency of 200 Hz. From 100-2000 individual spectra were obtained.
  • TOF / TOF tandem flight time mode
  • the precursors were accelerated to 8 kV and selected at the ion gateway.
  • the collision-generated fragments of the precursors with air (CID) in the collision-induced dissociation "were also accelerated to 15kV at source 2 and their masses were analyzed after passing through the ion reflector. Automatic mass data analysis was performed using the "4000 Series Explorer" version 3.5.3 software (Applied Biosystems).
  • fragment ion spectra obtained from the "Glub-fibrinopeptide" (4800MALDI / TOF-TOF, Applied Biosystem) were used.
  • the MALDI-MS and MS / MS data were combined using the "GPS Explorer" version 3.6 program, which allows non-redundant searches in the Swissprot 56.2 protein database using the Mascot version 2.2 (Matrix science) program, with a mass tolerance of 50 ppm and allowing the loss of a cutting place.
  • MALDI-MS / MS spectra and searches were manually reviewed in detail using this program.
  • EXAMPLE 2 Detection and quantification of ⁇ -1-antichymotrypsin by immunoblot
  • valve leaflet with EA and a valve valve leaflet were dissected and cultured separately in RPMI-free amino acid medium and supplemented with labeled arginine and lysine, at 37 0 C.
  • Culture medium samples were collected at 24, 48, 72, 96 and 120 hours to find the maximum protein secretion time. This time turned out to be 96 hours.
  • the proteins were then stained by dipping the nitrocellulose membranes in a solution of 0.2% Ponceau Red in 30% trichloroacetic acid (30%) and 30% (w / v) sulfosalicylic acid for 1 minute, after which membranes were washed with distilled water to remove excess dye. A digitized image of each membrane was taken with the GS-800 calibrated densitometer. The proteins were blocked using a phosphate buffer with 0.1% Tween20 (v / v) and with 7.5% skimmed milk powder (w / v) for 1 hour under stirring at room temperature. The membranes were washed 3 times for 10 minutes in a phosphate buffer with 0.1% Tween20 (v / v).
  • the membranes were incubated for 1 hour at room temperature with the specific antibody against ⁇ -1-antichymotrypsin, diluted 1: 1000 in the wash buffer with 5% (w / v) skimmed milk powder. After performing another 3 10-minute washes in the wash buffer, the membranes were incubated for 1 hour at room temperature with the corresponding secondary antibody (anti-rabbit antibody developed in goat and bound to peroxidase), diluted 1: 5,000 in buffer Wash with 5% (w / v) skimmed milk powder. Finally, after another 3 washes of 10 minutes, the membranes were revealed using the chemiluminescent substrate ECL (GE Healthcare).
  • the intensities of the bands were quantified by performing a densitometry of each of them and subtracting the background noise using the Quantity One 4.6.5 program.
  • the results obtained, measured in intensity * mm 2 were analyzed with the GraphPad Prism 4.0 statistical analysis software, using a non-parametric T test to determine significant differences with p ⁇ 0.05 values.
  • EXAMPLE 3 Immunohistochemistry against ⁇ -1 -antichymotrypsin in healthy and stenotic aortic valve tissue
  • Tissue sections both of stenotic aortic valves and control aortic valves, of 6 ⁇ thickness fixed in formalin were used, previously descaled in Shandon-TBD1 (Thermo Scientific), embedded in OCT and frozen in liquid nitrogen. Sections were blocked in phosphate buffer with Tween 20 (0.1%) with 1% BSA for 1 hour. Subsequently, the tissue sections were incubated with the primary antibody 1 hour at room temperature. Finally, the sections were incubated with the secondary antibody IgG-HRP-conjugate. The development was performed by adding the 3-3 diaminobenzidine chromogen. The cuts were stained with hematoxylin and dehydrated in a gradient of alcohols (70%, 95%, absolute alcohol). Finally, the cuts were washed in xylol and mounted with DPX mounting medium, to seal the glass sheets with the fabric. As a negative control, the entire immunohistochemical procedure was performed in the absence of the primary antibody ( Figure 2).
  • EXAMPLE 4 Detection and quantification of ⁇ -1-antichymotrypsin in plasma samples of aortic valves of patients with AD and of MRM control individuals ("Multiple Reaction Monitorinq")
  • Proteins plasma samples were reduced and alkylated with 100 mM DTT in 50 mM ammonium bicarbonate for 30 minutes at 37 0 C, followed by iodoacetamide in 550 mM ammonium bicarbonate 50 mM at room temperature in the dark for 20 minutes. After that time, 60% 50 mM ammonium bicarbonate and 15% acetonitrile were added to the samples and then a modified porcine trypsin solution (1 g / l) with a ratio of ⁇ g trypsin / 50 ⁇ g protein was added. Digestion was incubated at 37 0 C for at least 6 hours (usually overnight).
  • the reaction was stopped by adding 2% formic acid and the samples were cleaned using centrifuge micro columns (spin-columns) with C18 resin (Pep-Clean, Pierce).
  • the triptych digested was vacuum dried in a "speed-vac” centrifuge and resuspended in a 2% acetonitrile solution with 2% formic acid.
  • the LC-MS / MS system consists of a nano-LC TEMPO (Applied Biosystems) system combined with a nano-autosampler. Three injections of each digested (2 ⁇ g in each injection) were performed using mobile phase A (2% acetonitrile, 0.1% formic acid) with a flow of 10 ⁇ / minute for 5 minutes. The peptides were thus loaded into a C18 pre-column to pre-concentrate and desalt the samples.
  • peptides were separated by Reverse phase nanochromatography on a C18 capillary column, using mobile phase A (2% acetonitrile, 0.1% formic acid) and mobile phase B (98% acetonitrile, 0.1% formic acid), with a flow of 300 nl / minute, applying the following gradient: 2- 15% B in the first 2 minutes, increasing to 50% B during the following 38 minutes, 50-90% B in 2 minutes, maintaining 95% B for 3 minutes, returning in 1 minute to initial conditions (2% B) and keeping them for 14 more minutes.
  • mobile phase A 2% acetonitrile, 0.1% formic acid
  • mobile phase B 98% acetonitrile, 0.1% formic acid
  • the LC-MS / MS analysis was performed on a hybrid triple quadrupole / linear ion trap AB / MDS Sciex 4000 Q TRAP with NanoSprayl l (Applied Biosystems) source. Both this system and the TEMPO nano-LC system are controlled by Analyst software v.1 .4.2. The acquisition was carried out in positive mode, with an ionization voltage of 2800 V, with a "curtain gas" of 10, a "nebulizer gas” of 20 and an "interface temperature" of 150 0 C. Nitrogen was used both in the case of collision gas as in that of "curtain gas”. MRM transitions were optimized for maximum transmission and sensitivity. The parameters were optimized for each of the transitions and are summarized in Table 3. A total of 3 MRM transitions (diagnostic fragments) per peptide were monitored for each individual sample, and with three replicates per sample (Table 4, Figure 4A) . Table 3 Proteotypic peptides and transitions analyzed by MRM.
  • AACT_1_T3 42469.24 64666.08 792452.81 1302423.44 0.064957265

Abstract

La présente invention concerne une méthode d'obtention de données utiles pour déterminer le risque de sténose aortique (SA), la présence de SA et/ou le pronostic du développement d'une SA, par détection et/ou quantification de la protéine α-1-antichimotrypsine. L'invention concerne également un kit pour le diagnostic et le pronostic de la SA.
PCT/ES2011/070365 2010-05-20 2011-05-20 Méthode pour le pronostic et le diagnostic de la sténose aortique dans laquelle l'alpha-1-antichimotrypsine est utilisée en tant que marqueur WO2011144791A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201030759 2010-05-20
ES201030759A ES2370671B1 (es) 2010-05-20 2010-05-20 Método de pronóstico y diagnóstico de la estenosis aórtica que comprende la alfa-1-antiquimiotripsina como marcador.

Publications (1)

Publication Number Publication Date
WO2011144791A1 true WO2011144791A1 (fr) 2011-11-24

Family

ID=44991233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070365 WO2011144791A1 (fr) 2010-05-20 2011-05-20 Méthode pour le pronostic et le diagnostic de la sténose aortique dans laquelle l'alpha-1-antichimotrypsine est utilisée en tant que marqueur

Country Status (2)

Country Link
ES (1) ES2370671B1 (fr)
WO (1) WO2011144791A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIL-DONES F. ET AL.: "Valvular aortic stenosis: a proteomic insight", CLINICAL MEDICINE INSIGHT: CARDIOLOGY, vol. 4, 4 February 2010 (2010-02-04), pages 1 - 7 *
IMAI K. ET AL.: "C-Reactive protein predicts severity, progression and prognosis of asymptomatic aortic valve stenosis", AMERICAN HEART JOURNAL, vol. 156, no. 4, October 2008 (2008-10-01), pages 713 - 718, XP025532747, DOI: doi:10.1016/j.ahj.2008.04.011 *
LIM P. ET AL.: "Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide", EUROPEAN HEART JOURNAL, vol. 25, no. 22, 2004, pages 2048 - 2053 *

Also Published As

Publication number Publication date
ES2370671B1 (es) 2012-10-30
ES2370671A1 (es) 2011-12-21

Similar Documents

Publication Publication Date Title
Tokushige et al. Discovery of a novel biomarker in the urine in women with endometriosis
Basagaña et al. Allergy to human seminal fluid: cross-reactivity with dog dander
ES2288358A1 (es) Marcadores de fibrosis.
ES2282780T3 (es) Metodo para el diagnostico de la fibrosis hepatica.
US20160003786A1 (en) Methods Of Detecting Cancer
Surin et al. LG 3 fragment of endorepellin is a possible biomarker of severity in I g A nephropathy
ES2535971T3 (es) Nuevos biomarcadores para la enfermedad de hígado graso no alcohólico y métodos para detectar la enfermedad de hígado graso no alcohólico que emplean dichos biomarcadores
Fernández-Grijalva et al. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer
US10054596B2 (en) Platelet biomarkers in cancer diagnosis
ES2361808B1 (es) Método de obtención de datos útiles para el diagnóstico o el pronóstico del c�?ncer colorrectal.
EP2603797B1 (fr) Procédé pour le diagnostic de l' il sec et de la blépharite
US20090280512A1 (en) Tumor marker for renal cancer and method for determination of occurrence of renal cancer
US20210270835A1 (en) Biomarkers for urothelial carcinoma and applications thereof
ES2364169B1 (es) Uso de las isoformas de apo j como biomarcadores de lesión tisular.
Wai-Hoe et al. Proteomics and detection of uromodulin in first-time renal calculi patients and recurrent renal calculi patients
ES2370671B1 (es) Método de pronóstico y diagnóstico de la estenosis aórtica que comprende la alfa-1-antiquimiotripsina como marcador.
TWI397687B (zh) 腎病變相關之生物標記的應用及其中所使用的套組
WO2010079253A2 (fr) Biomarqueurs pour le diagnostic de la fibrose
US8771968B2 (en) Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
ES2925148A1 (es) Metodo de diagnostico, pronostico o prediccion de la evolucion de la estenosis aortica
KR20130102693A (ko) 유방암 진단용 단백질 마커 아포리포단백질 （ａ）, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
US20060046276A1 (en) Acetyl-LDL receptor as a biomarker for breast cancer
JP2023153066A (ja) 細胞外小胞新規大動脈瘤マーカーとしてのｎｏｓ３
黒光貞夫 The Analysis of Urinary Factor of Interstitial Cystitis Patient
JP2008275413A (ja) 扁平上皮癌の診断用キット及び判定方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11783122

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11783122

Country of ref document: EP

Kind code of ref document: A1